Trials / Completed
CompletedNCT00867698
AST-120 Used to Treat Mild Hepatic Encephalopathy
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy, Safety and Tolerability of AST-120 (Spherical Carbon Adsorbent) for 8 Weeks in the Treatment of Mild Hepatic Encephalopathy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 148 (actual)
- Sponsor
- Ocera Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether AST-120 is safe and effective in the treatment of mild hepatic encephalopathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AST-120 | AST-120 |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2010-04-01
- Completion
- 2010-06-01
- First posted
- 2009-03-24
- Last updated
- 2014-06-18
Locations
38 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00867698. Inclusion in this directory is not an endorsement.